Glatiramer acetate-specific human CD8+ T cells: Increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment

Journal of Neuroimmunology

Volumn 181, Issue 1-2, 2006, Pages 133-140

  Dressel, Alexander ^a   Vogelgesang, Antje ^a   Brinkmeier, Heinrich ^b   Mäder, Michael ^c   Weber, Frank ^d  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

CD8+ T cells; Glatiramer acetate; IFN ; IL 10; IL 4; Multiple sclerosis

Indexed keywords

CYTOKINE; GLATIRAMER; INTERLEUKIN 4; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANALYTIC METHOD; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CLONING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HLA SYSTEM; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; CLONE CELLS; EPITOPES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-4; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES;

EID: 34447309805     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.07.014     Document Type: Article

References (45)

1. Allie R., Hu L., Mullen K.M., Dhib-Jalbut S., and Calabresi P.A. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy. Arch. Neurol. 62 (2005) 889-894
2. Antel J., Bania M., Noronha A., and Neely S. Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis. J. Immunol. 137 (1986) 3436-3439
3. Babbe H., Roers A., Waisman A., Lassmann H., Goebels N., Hohlfeld R., Friese M., Schroder R., Deckert M., Schmidt S., Ravid R., and Rajewsky K. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192 (2000) 393-404
4. Balashov K.E., Khoury S.J., Hafler D.A., and Weiner H.L. Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J. Clin. Invest. 95 (1995) 2711-2719
5. Balashov K.E., Comabella M., Ohashi T., Khoury S.J., and Weiner H.L. Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS. Neurology 55 (2000) 192-198
6. Bieganowska K.D., Ausubel L.J., Modabber Y., Slovik E., Messersmith W., and Hafler D.A. Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. J. Exp. Med. 185 (1997) 1585-1594
7. Bitsch A., Schuchardt J., Bunkowski S., Kuhlmann T., and Bruck W. Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 123 (2000) 1174-1183
8. Crawford M.P., Yan S.X., Ortega S.B., Mehta R.S., Hewitt R.E., Price D.A., Stastny P., Douek D.C., Koup R.A., Racke M.K., and Karandikar N.J. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 103 (2004) 4222-4231
9. Dressel A., Chin J.L., Sette A., Gausling R., Hollsberg P., and Hafler D.A. Autoantigen recognition by human CD8 T cell clones: enhanced agonist response induced by altered peptide ligands. J. Immunol. 159 (1997) 4943-4951
10. Duda P.W., Schmied M.C., Cook S.L., Krieger J.I., and Hafler D.A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 105 (2000) 967-976
11. Farina C., Then Bergh F., Albrecht H., Meinl E., Yassouridis A., Neuhaus O., and Hohlfeld R. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain 124 (2001) 705-719
12. Goodin D.S., Frohman E.M., Garmany Jr. G.P., Halper J., Likosky W.H., Lublin F.D., Silberberg D.H., Stuart W.H., and van den Noort S. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58 (2002) 169-178
13. Hafler D.A. Degeneracy, as opposed to specificity, in immunotherapy. J. Clin. Invest. 109 (2002) 581-584
14. Hafler D.A. Multiple sclerosis. J. Clin. Invest. 113 (2004) 788-794
15. Hollsberg P., Weber W., Dangond F., Batra V., Sette A., and Hafler D. Differential activation of proliferation and cytotoxicity in human T-cell lymphotropic virus type I tax-specific CD8 T cells by an altered peptide ligand. PNAS 92 (1995) 4036-4040
16. Huseby E.S., Liggitt D., Brabb T., Schnabel B., Ohlen C., and Goverman J. A pathogenic role for myelin-specific CD8+ T cells in a model for multiple sclerosis. J. Exp. Med. 194 (2001) 669-676
17. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J.W., and Schiffer R.B. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 (1995) 1268-1276
18. Johnson K.P., Brooks B.R., Ford C.C., Goodman A., Guarnaccia J., Lisak R.P., Myers L.W., Panitch H.S., Pruitt A., Rose J.W., Kachuck N., and Wolinsky J.S. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult. Scler. 6 (2000) 255-266
19. Jung S., Siglienti I., Grauer O., Magnus T., Scarlato G., and Toyka K. Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate. J. Neuroimmunol. 148 (2004) 63-73
20. Jurewicz A., Biddison W.E., and Antel J.P. MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J. Immunol. 160 (1998) 3056-3059
21. Karandikar N.J., Crawford M.P., Yan X., Ratts R.B., Brenchley J.M., Ambrozak D.R., Lovett-Racke A.E., Frohman E.M., Stastny P., Douek D.C., Koup R.A., and Racke M.K. Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patients with multiple sclerosis. J. Clin. Invest. 109 (2002) 641-649
22. Kuhlmann T., Lingfeld G., Bitsch A., Schuchardt J., and Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125 (2002) 2202-2212
23. Medana I., Martinic M.A., Wekerle H., and Neumann H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am. J. Pathol. 159 (2001) 809-815
24. Miller A., Shapiro S., Gershtein R., Kinarty A., Rawashdeh H., Honigman S., and Lahat N. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol. 92 (1998) 113-121
25. Monteiro J., Hingorani R., Pergolizzi R., Apatoff B., and Gregersen P.K. Clonal dominance of CD8+ T-cell in multiple sclerosis. Ann. N.Y. Acad. Sci. 756 (1995) 310-312
26. Neuhaus O., Farina C., Yassouridis A., Wiendl H., Then Bergh F., Dose T., Wekerle H., and Hohlfeld R. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7452-7457
27. Neuhaus O., Farina C., Wekerle H., and Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56 (2001) 702-708
28. Romani N., Gruner S., Brang D., Kampgen E., Lenz A., Trockenbacher B., Konwalinka G., Fritsch P.O., Steinman R.M., and Schuler G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180 (1994) 83-93
29. Sad S., Marcotte R., and Mosmann T.R. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 2 (1995) 271-279
30. Scholz C., Patton K.T., Anderson D.E., Freeman G.J., and Hafler D.A. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J. Immunol. 160 (1998) 1532-1538
31. Segal B.M. Experimental autoimmune encephalomyelitis: cytokines, effector T cells, and antigen-presenting cells in a prototypical Th1-mediated autoimmune disease. Curr. Allergy Asthma Rep. 3 (2003) 86-93
32. Skulina C., Schmidt S., Dornmair K., Babbe H., Roers A., Rajewsky K., Wekerle H., Hohlfeld R., and Goebels N. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2428-2433
33. Steinman L. Myelin-specific CD8 T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis. J. Exp. Med. 194 (2001) F27-F30
34. Sun D., Whitaker J.N., Huang Z., Liu D., Coleclough C., Wekerle H., and Raine C.S. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J. Immunol. 166 (2001) 7579-7587
35. Teitelbaum D., Aharoni R., Arnon R., and Sela M. Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 9724-9728
36. Tsuchida T., Parker K.C., Turner R.V., McFarland H.F., Coligan J.E., and Biddison W.E. Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides [published erratum appears in Proc Natl Acad Sci U S A 1995 Sep 26;92(20):9432]. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 10859-10863
37. Vandevyver C., Mertens N., van den Elsen P., Medaer R., Raus J., and Zhang J. Clonal expansion of myelin basic protein-reactive T cells in patients with multiple sclerosis: restricted T cell receptor V gene rearrangements and CDR3 sequence. Eur. J. Immunol. 25 (1995) 958-968
38. Vieira P.L., Heystek H.C., Wormmeester J., Wierenga E.A., and Kapsenberg M.L. Glatiramer acetate (copolymer-1, Copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J. Immunol. 170 (2003) 4483-4488
39. Wallstrom E., Khademi M., Andersson M., and Olsson T. Increased numbers of mononuclear cells from blood and CSF expressing interferon-gamma mRNA in multiple sclerosis are from both the CD4+ and the CD8+ subsets. Eur. J. Neurol. 7 (2000) 71-76
40. Weber F., Polak T., Gunther A., Kubuschok B., Janovskaja J., Bitsch A., Poser S., and Rieckmann P. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis [see comments]. Ann. Neurol. 44 (1998) 27-34
41. Weber M.S., Starck M., Wagenpfeil S., Meinl E., Hohlfeld R., and Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 127 (2004) 1370-1378
42. Wekerle H., Kojima K., Lannes-Vieira J., Lassmann H., and Linington C. Animal models. Ann. Neurol. 36 (1994) S47-S53 (Suppl)
43. Windhagen A., Scholz C., Hollsberg P., Fukaura H., Sette A., and Hafler D.A. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 2 (1995) 373-380
44. Wucherpfennig K.W., Zhang J., Witek C., Matsui M., Modabber Y., Ota K., and Hafler D.A. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J. Immunol. 152 (1994) 5581-5592
45. Zang Y.C., Li S., Rivera V.M., Hong J., Robinson R.R., Breitbach W.T., Killian J., and Zhang J.Z. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J. Immunol. 172 (2004) 5120-5127